BigHat Biosciences has teamed up with Janssen Biotech in a strategic collaboration to develop novel therapeutics using the companies' combined expertise in drug discovery and AI/ML. The terms and financial details of the partnership have not been disclosed.
This collaboration targets the discovery and verification of potential proteins, as well as simplifying the design of antibodies and other treatments for a range of conditions, from chronic illnesses to life-threatening diseases. It hopes to achieve this by using BigHat's proprietary AI/ML-powered platform, Milliner, and Janssen’s drug development and data science expertise.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.